Q BioMed
Q BioMed is a publicly traded, pre-revenue biomedical development company that develops radiopharmaceutical therapies, with Strontium89 for metastatic bone pain as its lead asset. It targets cancer patients and the providers serving them, aiming for worldwide commercialization.
- Company typePublic
- Founded2014
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Q BioMed firmographics
Firmographics- Name
- Q BioMed
- Legal name
- Q BioMed Inc.
- Website
- https://qbiomed.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Q BioMed is a publicly traded, pre-revenue biomedical development company that develops radiopharmaceutical therapies, with Strontium89 for metastatic bone pain as its lead asset. It targets cancer patients and the providers serving them, aiming for worldwide commercialization.
- Ownership category
- akta.pro rank
Q BioMed industry classification
Industry- Product category
- Radiopharmaceutical Therapies
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)
Keywords
Where Q BioMed is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Q BioMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales
Revenue model
- Drug Development and Commercialization: Q BioMed is a pre-revenue biotech company developing pharmaceutical products including Strontium89 for cancer treatment. The company currently has no revenue but is working to advance its drug pipeline toward commercialization.
Go-to-market motion1 record
Q BioMed product offering
Product offeringCore offering
Q BioMed is a biomedical acceleration and development company developing pharmaceutical products for cancer treatment, with Strontium89—a radiopharmaceutical therapy for metastatic bone pain—as its primary commercial asset. The company is executing a worldwide rollout of Strontium89 and advancing additional pipeline assets toward commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- Strontium89 A radiopharmaceutical therapy intended for the treatment of metastatic bone pain, positioned as Q BioMed's lead commercial asset and being rolled out worldwide as part of the company's drug commercialization efforts. It is targeted at healthcare providers—primarily oncologists, nuclear medicine specialists, and hospitals—serving cancer patients with bone metastases.
Companies that use Q BioMed
Customer profileSegments1 record
Ideal customer profiles1 record
Q BioMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Q BioMed partnerships and signals
Strategic signalScale indicators4 records
Q BioMed competitors and assessment
Company assessmentDirect peers
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic radioligands for cancer. Direct competitor to Q BioMed in the therapeutic radiopharmaceutical space and the closest publicly traded pure-play comparable.
- Lantheus Holdings: Specialty radiopharmaceutical company with both diagnostic and therapeutic radiopharma assets, including bone and oncology franchises. Comparable to Q BioMed as a focused radiopharma operator targeting oncology indications.
- Curium Pharma: World's largest radiopharmaceutical manufacturer with a broad portfolio of diagnostic and therapeutic nuclear medicine products. Comparable as a vertically integrated radiopharma operator with both manufacturing and commercial reach.
Broad incumbents
- Novartis: Global pharmaceutical incumbent owning Lutathera and Pluvicto, the leading commercial radioligand therapies. Defines the standard Q BioMed must compete against in therapeutic radiopharmaceuticals and represents a likely strategic acquirer.
- Bayer: Markets Xofigo (radium-223), a radiopharmaceutical for bone metastases in prostate cancer — the most direct therapeutic substitute for Strontium89 in the metastatic bone pain indication Q BioMed targets.
- Bracco Imaging: Global imaging and radiopharmaceutical company with a portfolio of diagnostic nuclear medicine products. Comparable as an established radiopharma player with the manufacturing and distribution scale Q BioMed lacks.
- Cardinal Health (Nuclear & Precision Health): Operates one of the largest U.S. radiopharmacy networks distributing Strontium-89 and other therapeutic radiopharmaceuticals. Comparable as a critical commercial channel partner and direct competitor for bone-pain radiotherapeutics.
- GE HealthCare:
Emerging players
- ITM Isotope Technologies Munich: Clinical-stage radiopharma company developing therapeutic and diagnostic radioisotopes for oncology. Comparable emerging pure-play radiopharma with similar therapeutic focus to Q BioMed's pipeline.
- Fusion Pharmaceuticals: Clinical-stage developer of targeted alpha therapies (conjugates) for cancer. Comparable emerging radiopharma peer with overlapping therapeutic oncology focus and similar development-stage profile.
Market position
Customer concentration
Q BioMed social profiles
Digital presenceQ BioMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Q BioMed leadership team
Management profileNumber of profiles
Profiles2 records
Q BioMed funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Q BioMed M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Q BioMed
What does Q BioMed do?
Q BioMed is a biomedical acceleration and development company developing pharmaceutical products for cancer treatment, with Strontium89—a radiopharmaceutical therapy for metastatic bone pain—as its primary commercial asset. The company is executing a worldwide rollout of Strontium89 and advancing additional pipeline assets toward commercialization.
Is Q BioMed a public or private company?
Q BioMed is a public company. It is classified as public and is currently operating.
When was Q BioMed founded?
Q BioMed was founded in 2014. It employs 11 to 50 people.
Where is Q BioMed based?
Q BioMed is headquartered in New York, United States, in the North America region.
How does Q BioMed make money?
One revenue line is on record: drug Development and Commercialization.
Who are Q BioMed's main competitors?
Direct peers on record are Telix Pharmaceuticals, Lantheus Holdings and Curium Pharma. Broad incumbents are Novartis, Bayer, Bracco Imaging, Cardinal Health (Nuclear & Precision Health) and GE HealthCare. Emerging players are ITM Isotope Technologies Munich and Fusion Pharmaceuticals.
Does Q BioMed have an API?
No public API is recorded for Q BioMed.
What industry is Q BioMed in?
Q BioMed's product category is Radiopharmaceutical Therapies. Its primary akta.pro industry code is HLAIAGAE, Radiopharmacy Compounding & Dispensing (Hospital/Commercial). Its NAICS code is 3254 and its SIC code is 2834.